Oct 9, 2008 - Regulatory News: EpiCept Corporation today announced that the European Commission has granted a full marketing authorization in the form of a positive Commission Decision, for Ceplene(R) (histamine dihydrochloride) for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission.
The details can be read here.
No comments:
Post a Comment